Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 1/2 10Phase 3 6Phase 4 3Phase NA 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 1Lymphoma, T-Cell, Peripheral 1Hodgkin Disease 1

Interventions

Radiosurgery 58Radiotherapy 43Magnetic Resonance Spectroscopy 39Cyclophosphamide 34Standard of Care 30Surveys and Questionnaires 22Dexamethasone 19Educational Status 18Therapeutics 17Exercise 17Radiation 16Magnetic Resonance Imaging 16fludarabine phosphate 15Proton Therapy 15Practice Guidelines as Topic 15Methods 15Mammography 15Fluorodeoxyglucose F18 15Cisplatin 15Blood Specimen Collection 15Acupuncture Therapy 15Doxorubicin 14fludarabine 13Positron-Emission Tomography 13Calcium Dobesilate 13Biopsy 13Surgical Procedures, Operative 12Radiotherapy, Intensity-Modulated 12Palliative Care 12Indocyanine Green 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase NA × Has results × Brentuximab Vedotin × Clear all
NCT01578967 2021-12-07

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
41 enrolled 14 charts
Lymphoid

Hodgkin Disease

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Terminated
1 enrolled 5 charts
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡